Company: IMRX
Filing Date: 2025-09-08
Form Type: 424B3
Source: 0001104659-25-088317
Chunk: 23

Company: Immuneering Corp
Filing Date: 2025-09-08
Form: 424B3
Chunk 23
---
 to the Company subject to the terms of such warrants, provided that such percentage may in no event exceed 9.99% (the “Beneficial Ownership Limitation”).

<div align='center'>16</div>

TABLE OF CONTENTS

On August 21, 2025, in connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with all of the Investors. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) within 30 days after the Closing Date, for purposes of registering the resale of the Shares and the shares of Class A common stock issuable upon exercise of the Pre-Funded Warrants and Purchase Warrants (the “Warrant Shares”) purchased by the Investors in the Private Placement, and any shares of Class A common stock issued as a dividend or other distribution with respect to, in exchange for or in replacement of such Shares or Warrant Shares. The Company agreed to use commercially reasonable efforts to cause such registration statement to be declared effective by the SEC within 60 days after the Closing Date, or 90 days after the Closing Date if the SEC reviews the registration statement. The Company has also agreed to, among other things, indemnify each Investor, its officers, directors, members, managers, partners, trustees, employees and agents and other representatives, successors and assigns, and each other person, if any, who controls such Investor within the meaning of the Securities Act, under the registration statement against certain liabilities incident to the Company’s obligations under the Registration Rights Agreement.

The Private Placement was exempt from registration pursuant to Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder, as a transaction by an issuer not involving a public offering. The Investors have not acquired the securities with a view to or for sale in connection with any distribution thereof in violation of the Securities Act and appropriate legends have been affixed to the securities issued in this transaction.

<div align='center'>17</div>

TABLE OF CONTENTS

### SELLING STOCKHOLDERS
The shares of Class A common stock being offered by the Selling Stockholders (the “Selling Stockholders”) are those previously issued to the Selling Stockholders or issuable upon exercise of warrants previously issued to the Selling Stockholders. For additional information regarding the issuances of those shares of common stock, see “Private Placement of Securities” above. The term “Selling Stockholders” includes